Oncology Strategy
Leading Oncology Innovation, Access, and Market Success
Oncology manufacturers are under increasing pressure to demonstrate the clinical and economic value of their therapies amid rising treatment costs and the complexities of precision medicine. In this highly competitive and evolving landscape, trust The Dedham Group to be your strategic partner for success. As pioneers in the oncology industry with decades of experience across hundreds of launches and indication expansions, we are the go-to experts for overcoming the toughest market challenges. Our unmatched expertise in navigating evolving landscape changes, complex drug delivery models, and payer access allows us to position your product for maximum impact.
Schedule a Meeting
Strategic Areas of Focus:
Oncology is provider-driven, and understanding evolving operational models (e.g., pathways, EMR order sets, biomarker testing) is key for effective targeting.
As cancer treatments grow more complex and costly, clinical pathways increasingly influence healthcare provider decision-making.
Payers are adapting their oncology management strategies (e.g., pathways, OBM/LBM), potentially implementing stricter restrictions in competitive indications.
Manufacturers are focusing on innovative GPO contracts and non-discount models to incentivize access and engage practice groups.
Oncology requires high-touch patient support services to improve treatment adherence and outcomes.
Effective distribution models are essential for the successful delivery of complex oncology therapies.
Maximizing biomarker testing rates through oncologist and pathologist engagement is essential for successful launches of targeted therapies.
New therapies like radioligand treatments, bispecific antibodies, and personalized cancer vaccines drive innovation but create challenges for adoption and access.
We Provide:
Pioneers in Oncology Strategy
Dedicated Oncology Stakeholder Panel
Curated Oncology Datasets
Related Resources:
The Evolving Role of Oncology Clinical Pathways in Value-Based Care
In recent years, healthcare providers, payers, and policymakers have increasingly shifted focus from delivering volume-based care to delivering value-based care. This transition, moving from traditional fee-for-service to models that prioritize quality and efficiency, has created a need for care models that deliver high-quality care while managing costs.
Provider Rebate Aggregators: Implications for Manufacturers
The U.S. pharmaceutical drug channel is increasingly complex, involving numerous stakeholders and intricate agreements that impact the economics surrounding prescription drugs. As a result, it’s critical for manufacturers to understand the prevalence of these entities, and the impact they have on channel economics, particularly to their bottom line.
Evolving Payer Pressures on Patient Affordability: How Pharma Can Improve Access with Support Program Evolution
For some patients who are prescribed specialty therapies, insurance coverage limitations or cost share requirements prevent them from accessing necessary treatments. Here’s what manufacturers need to know about access landscape changes and evolving PSP solutions to safeguard patient access to treatment.
